A prospective, randomized, double-blinded, placebo controlled, phase III study to evaluate the efficacy and safety of apatinib plus best supportive care (BSC) compared to placebo plus BSC in patients with advanced or metastatic gastric cancer: The ANGEL study.

被引：5
|
作者：
Kang, Yoon-Koo
Boku, Narikazu
Kang, Won Ki
Yoon, Harry H.
Cascinu, Stefano
Al-Batran, Salah-Eddin
Houston, Scott
Park, Cheol Hee
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.TPS4138
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4138
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Randomized phase III ANGEL study of rivoceranib (apatinib) plus best supportive care (BSC) vs placebo plus BSC in patients with advanced/metastatic gastric cancer who failed ≥2 prior chemotherapy regimens
    Kang, Y-K.
    Kang, W. K.
    Di Bartolomeo, M.
    Chau, I.
    Yoon, H. H.
    Cascinu, S.
    Ryu, M-H.
    Kim, J. G.
    Lee, K-W.
    Oh, S. C.
    Takashima, A.
    Kryzhanivska, A.
    Chao, Y.
    Vladimirov, V.
    Evesque, L.
    Schenker, M.
    McGinn, A.
    Sankar, N.
    Wyrwicz, L.
    Boku, N.
    ANNALS OF ONCOLOGY, 2019, 30
  • [2] Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study
    Ciuleanu, T. E.
    Brodowicz, T.
    Belani, C. P.
    Kim, J.
    Krzakowski, M.
    Laack, E.
    Wu, Y.
    Peterson, P.
    Adachi, S.
    Zielinski, C. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC)
    Belani, C. P.
    Brodowicz, T.
    Ciuleanu, T.
    Kim, J. H.
    Krzakowski, M.
    Laack, E.
    Wu, Y. L.
    Peterson, P.
    Krejcy, K.
    Zielinski, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC)
    Belani, C. P.
    Brodowicz, T.
    Ciuleanu, T.
    Kim, J. H.
    Krzakowski, M.
    Laack, E.
    Wu, Y. L.
    Peterson, P.
    Krejcy, K.
    Zielinski, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
  • [5] RESULTS OF A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL (CORRECT) OF REGORAFENIB PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) WHO HAVE PROGRESSED AFTER STANDARD THERAPIES
    Yoshino, T.
    Van Cutsem, E.
    Sobrero, A. F.
    Siena, S.
    Falcone, A.
    Ychou, M.
    Lenz, H. -J.
    Cihon, F.
    Wagner, A.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 7 - 7
  • [6] LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies.
    Lenz, Heinz-Josef
    Tabernero, Josep
    Yoshino, Takayuki
    Oum'Hamed, Zohra
    Vlassak, Soetkin
    Sassi, Mouna
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies.
    Lenz, Heinz-Josef
    Tabernero, Josep
    Yoshino, Takayuki
    Oum'Hamed, Zohra
    Vlassak, Soetkin
    Sassi, Mouna
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [8] Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies
    Hofheinz, R.
    Grothey, A.
    Sobrero, A. F.
    Siena, S.
    Falcone, A.
    Ychou, M.
    Lenz, H. -J
    Yoshino, T.
    Cihon, F.
    Strauss, U. P.
    Van Cutsem, E.
    ONKOLOGIE, 2012, 35 : 255 - 255
  • [9] A Multicenter, Randomized, Double-blind, Phase II Study of TAS-102 (A) Plus Best Supportive Care (BSC) Versus Placebo (P) Plus BSC in Patients (pts) With Chemotherapy-refractory Metastatic Colorectal Cancer (mCRC)
    Kuboki, Y.
    Yoshino, T.
    Yamazaki, K.
    Nishina, T.
    Komatsu, Y.
    Baba, H.
    Tsuji, A.
    Yamaguchi, K.
    Muro, K.
    Ohtsu, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S392 - S392
  • [10] Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.
    Grothey, Axel
    Sobrero, Alberto F.
    Siena, Salvatore
    Falcone, Alfredo
    Ychou, Marc
    Lenz, Heinz-Josef
    Yoshino, Takayuki
    Cihon, Frank
    Wagner, Andrea
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
12345